Hit Identification – SARM1 Structural Elucidation By Internal Cryo-EM Platform

Blog details
2 min read
Share this:
Case Study: First Demonstration of SARM1 MOA: Advancing Therapeutic Discovery through XtalPi’s AI-Enhanced Cryo-EM Platform

SARM1 is an emerging protein target for neurodegenerative disorders and notorious for its complexity in capturing conformational heterogeneity and its active conformer, resolution limits for small domains, and intensive data processing demands. Explore how we demonstrate SARM1’s MOA by elucidating the SARM1-inhibitor complex structure.

XtalPi’s Solution:

Our AI-powered Cryo-EM platform reveals the high-resolution structure of non-covalent small molecule inhibitor binding to SARM1, significantly advancing target validation, rational drug design, and predictive modeling. It also provides critical mechanistic insights, identifies new therapeutic targets, and supports biomarker discovery.

Our Results:

  • A small molecule inhibitor-ADPR product was generated through a SARM1-catalyzed base-exchange reaction, marking the first demonstration of SARM1’s mechanism of action (MOA).
  • The AI-driven image processing module enhances efficiency by shortening the image processing timeline by two-fold.
  • Achieved a higher resolution structure of the SARM1-Inhibitor complex at 2.8 Å.

Your next success starts here

Recommended articles

How XtalPi Utilized MicroED to Tackle Different Polymorphism Challenges
Accelerated Identification of the Most Stable Remdesivir Polymorph in 33 Days Using an Integrated Experimental and Computational Approach
Hit Identification – Novel Hits for GPX4
Application Note: DEL Screening